Skip to content

Study · Animal study (in vivo) · mouse · 2002

4 results

Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.

Wells A, Souto JC, Solava J, Kassis J, Bailey KJ, Turner T

Clinical cancer research : an official journal of the American Association for Cancer Research1 Apr 2002Cited by 27 (Europe PMC)

PMID11948140 (opens in a new tab)PepBankPUB-11948140
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In athymic mice, goserelin inhibited tumors expressing wild-type EGFR.

    In plain wordsIn mice, goserelin inhibited tumors expressing wild-type EGFR.

    Peptide
    Goserelin
    Outcome
    DecreaseWild-type EGFR tumor growth
    Study

    mousen: not reported in source

    DU-145 xenografts in athymic mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    DU-145 cells, overexpressing wild-type EGFR, formed tumors in athymic mice that were inhibitable by goserelin acetate (Zoladex).
    1 context sentence
    Summary · context
    DU-145 cells stably expressing wild-type and A654 EGFR were grown as xenografts in the s.c. space of athymic mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In athymic mice, tumors expressing A654 EGFR resisted growth inhibition by goserelin.

    In plain wordsIn mice, tumors expressing A654 EGFR resisted growth inhibition by goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeA654 EGFR tumor growth
    Study

    mousen: not reported in source

    DU-145 xenografts in athymic mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tumors expressing the A654 EGFR were resistant to this growth inhibition.
    2 context sentences
    Summary · context
    DU-145 cells, overexpressing wild-type EGFR, formed tumors in athymic mice that were inhibitable by goserelin acetate (Zoladex).
    Summary · context
    DU-145 cells stably expressing wild-type and A654 EGFR were grown as xenografts in the s.c. space of athymic mice.
  3. 03LabIn vitro (cells)Efficacy outcome

    In vitro, goserelin acetate blocked proliferation of wild-type DU-145 cells.

    In plain wordsIn cells, goserelin acetate blocked proliferation of wild-type DU-145 prostate cancer cells.

    Peptide
    Goserelin
    Outcome
    DecreaseWild-type DU-145 cell proliferation
    Study

    humann: not reported in source

    WT DU-145 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These results paralleled in vitro studies in which goserelin acetate blocked proliferation of the WT DU-145 but not A654 DU-145 cells.
  4. 04LabIn vitro (cells)Efficacy outcome

    In vitro, goserelin acetate did not block proliferation of A654 DU-145 cells.

    In plain wordsIn cells, goserelin acetate did not block proliferation of A654 DU-145 prostate cancer cells.

    Peptide
    Goserelin
    Outcome
    No significant changeA654 DU-145 cell proliferation
    Study

    humann: not reported in source

    A654 DU-145 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These results paralleled in vitro studies in which goserelin acetate blocked proliferation of the WT DU-145 but not A654 DU-145 cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.